Psoriasis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are Japanese and are 18 years of age or older
- A doctor has diagnosed you with plaque psoriasis
- You are about to start treatment with either deucravacitinib or apremilast (as directed by your doctor and the medication's approved guidelines) for the first time
- You have read, understood, and signed a consent form agreeing to take part in the study
Who may not be able to join:
- You are currently taking part in, or planning to take part in, another clinical trial that involves a medical treatment or intervention
- You are already enrolled in a specific post-marketing surveillance study for deucravacitinib (a separate study listed as NCT05633264)
- You have previously taken the medication you would be assigned to in this trial — for example, if you have taken apremilast before, you would not be eligible for the apremilast part of the study, and the same applies to deucravacitinib
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb
Phone: 855-907-3286
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in percent Body Surface Area (BSA) involved affected by plaque psoriasis from baseline to follow up in participants treated with deucravacitinib.; Number of participants who achieved Physician's Global Assessment (PGA) of 0/1 from baseline to follow-up; Number of participants who achieved Absolute Psoriasis Area and Severity Index (aPASI) of ≤2 from baseline to follow-up; Number of participants who achieved Dermatology Life Quality Index (DLQI) of 0 /1 from baseline to follow-up; Participant duration of treatment (time difference between date of treatment initiation to date of discontin...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.